Hepatitis C News and Research

Latest Hepatitis C News and Research

Hepatitis C from anesthetist case assumes new proportions

According to Victoria’s chief health officer yesterday, another 1,100 people would be screened for hepatitis C that could have come from contact with an infected doctor at more than one clinic.

24 Oct 2010

Medivir reports consolidated net sales of SEK 54.7M

Medivir AB , a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its interim report today for the period covering 1 January - 30 September and a business update for the third quarter 2010.

22 Oct 2010

AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease

AiCuris announced today that its novel HCMV inhibitor AIC246 has been used successfully to treat a patient with multi-organ HCMV disease caused by multi-resistant virus. Details will be presented at the 48th IDSA meeting on October 23, presentation number LB-38.

22 Oct 2010

CIHR, RX&D - HRF to fund research projects on mental illness, palliative care

Six research projects on co-existing heath problems associated with mental illness and one project on palliative care among First Nations received over $9 million in funding announced today. This amount is provided by the Canadian Institutes of Health Research and the Rx&D Health Research Foundation.

22 Oct 2010

Regulus present advancements in microRNA platform at Oligonucleotide Therapeutics Society meeting

Regulus Therapeutics Inc. announced today that advancements from its leading microRNA platform and product pipeline were presented at the "6th Annual Meeting of the Oligonucleotide Therapeutics Society" held October 20 - 23, 2010 in Dana Point, California.

22 Oct 2010

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

Intercell AG and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half of 2011.

21 Oct 2010

Study on health effects of alcohol consumption with HIV

Living with HIV is difficult under the best of circumstances, but for people carrying the virus, alcohol consumption can become particularly perilous in intricate ways that are only beginning to be understood. At the Brown Alcohol Research Center on HIV (ARCH) funded by a new $7.5-million, five-year grant from the National Institutes of Health, Brown University scientists will study the health effects of drinking with HIV and provide doctors and patients with the latest guidance their results suggest.

21 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended September 30, 2010. Total revenues for the third quarter of 2010 were $1.94 billion, up 8 percent compared to total revenues of $1.80 billion for the third quarter of 2009. Net income for the third quarter of 2010 was $704.9 million, or $0.83 per diluted share, compared to net income for the third quarter of 2009 of $673.0 million, or $0.72 per diluted share.

20 Oct 2010

Study finds adipose dysfunction linked to steatosis, necroinflammation in G1 CHC patients

Researchers at the University of Palermo in Italy provide the evidence that a higher visceral adiposity index score-a new index of adipose dysfunction-has a direct correlation with viral load and is independently associated with both steatosis and necroinflammatory activity in patients with genotype 1 chronic hepatitis C (G1 CHC).

20 Oct 2010

An overview on American College of Gastroenterology's Annual Scientific meeting

The association between obesity and gastrointestinal-related cancers and coronary artery disease; the link between an overweight or obese body mass index and the severity of Crohn's disease; and whether inflammatory bowel disease is an independent risk factor for coronary artery disease, were among the highlights of new research that was presented this week at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio.

19 Oct 2010

Micronics to advance PanNAT system for molecular diagnosis of infectious pathogens

Micronics, Inc., a development-stage company, today announced that the Department of Defense has awarded the company an Applied Research and Technology Development Award under the U.S. Army Medical Research and Materiel Command's Polytrauma and Blast Injury project for advancement of its PanNAT system for point-of-care molecular diagnosis of infectious pathogens.

19 Oct 2010

The state of sexually transmissible and blood-borne infections in Australia: the 2010 Surveillance Reports

Australia last year reported its largest number of new HIV cases since the early 1990s but has seen a reduction in cases of hepatitis, infectious syphilis and gonorrhoea, new data contained in HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2010 shows.

18 Oct 2010

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease.

18 Oct 2010

NanoViricides' President delivers speech at ASNM Second Annual Conference

NanoViricides, Inc. announced today that the Company President was invited to and presented a talk at the Second Annual Conference of the American Society for NanoMedicine (ASNM).

18 Oct 2010

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Nektar Therapeutics presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious side effects associated with traditional opioid therapies.

18 Oct 2010

Bioniche's research scientists give presentations at Modern Vaccine and Adjuvant Formulation Conference

Bioniche Life Sciences Inc. a research-based, technology driven Canadian biopharmaceutical company, today announced that two of its senior research scientists gave presentations at the Modern Vaccine and Adjuvant Formulation Conference in Cannes, France this week.

18 Oct 2010

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Nektar Therapeutics today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.

18 Oct 2010

Royal Cornwall Hospital receives grant to study Hepatitis E

Researchers from the Royal Cornwall Hospital in Truro have received a grant of -337,000 to carry out a two-year study with partners in Glasgow and Norwich into a rare form of Hepatitis - Hepatitis E. The grant has come from the Chief Scientist's Office for Scotland and will be divided between the three centres taking part in the study.

18 Oct 2010

Anadys prices underwritten public offering of common stock

Anadys Pharmaceuticals, Inc. announced today the pricing of its underwritten public offering of 13,888,889 shares of its common stock at a price to the public of $1.80 per share. The gross proceeds to Anadys from this offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

15 Oct 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Hepatitis C from anesthetist case assumes new proportions

Medivir reports consolidated net sales of SEK 54.7M

AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease

CIHR, RX&D - HRF to fund research projects on mental illness, palliative care

Regulus present advancements in microRNA platform at Oligonucleotide Therapeutics Society meeting

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

Study on health effects of alcohol consumption with HIV

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Study finds adipose dysfunction linked to steatosis, necroinflammation in G1 CHC patients

An overview on American College of Gastroenterology's Annual Scientific meeting

Micronics to advance PanNAT system for molecular diagnosis of infectious pathogens

The state of sexually transmissible and blood-borne infections in Australia: the 2010 Surveillance Reports

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

NanoViricides' President delivers speech at ASNM Second Annual Conference

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Bioniche's research scientists give presentations at Modern Vaccine and Adjuvant Formulation Conference

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Royal Cornwall Hospital receives grant to study Hepatitis E

Anadys prices underwritten public offering of common stock

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in